https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-09-11 / Front Oncol 2019;9:884
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-09-11 / Front Oncol 2019;9:8842019-09-11 00:00:002019-09-11 00:00:00Past, Current, and Future of Immunotherapies for Prostate Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-10-25 / Int. J. Radiat. Biol. 2019 Feb;95(2):193-200
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-10-25 / Int. J. Radiat. Biol. 2019 Feb;95(2):193-2002018-10-25 00:00:002018-10-25 00:00:00Capacitive hyperthermia as an alternative to brachytherapy in DNA damages of human prostate cancer cell line (DU-145)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-02-13 / Nat Rev Urol 2018 Apr;15(4):235-250
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-02-13 / Nat Rev Urol 2018 Apr;15(4):235-2502018-02-13 00:00:002018-02-13 00:00:00Potentiating prostate cancer immunotherapy with oncolytic viruses
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-02-08 / J Clin Oncol 36, 2018 (suppl 6S; abstr 219)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-02-08 / J Clin Oncol 36, 2018 (suppl 6S; abstr 219)2018-02-08 00:00:002018-02-08 00:00:00Myeloid and plasmacytoid dendritic cell vaccinations for castration-resistant prostate cancer patients.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-09-19 / J. Biotechnol. 2017 Oct;260:91-97
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-09-19 / J. Biotechnol. 2017 Oct;260:91-972017-09-19 00:00:002017-09-19 00:00:00Genetically engineered oncolytic Newcastle disease virus mediates cytolysis of prostate cancer stem like cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-09-01 / G Chir 2017 Sep-Oct;37(5):225-235
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-09-01 / G Chir 2017 Sep-Oct;37(5):225-2352017-09-01 00:00:002019-02-15 08:51:59Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-03-21 / Int. J. Urol. 2017 05;24(5):342-351
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-03-21 / Int. J. Urol. 2017 05;24(5):342-3512017-03-21 00:00:002017-03-21 00:00:00Current status of clinical trials assessing oncolytic virus therapy for urological cancers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-03-02 / Crit. Rev. Oncol. Hematol. 2017 May;113:292-303
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-03-02 / Crit. Rev. Oncol. Hematol. 2017 May;113:292-3032017-03-02 00:00:002019-02-15 08:51:58A comprehensive review of immunotherapies in prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-02-15 / Cytotherapy 2017 04;19(4):500-513
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-02-15 / Cytotherapy 2017 04;19(4):500-5132017-02-15 00:00:002019-02-15 08:53:07Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-01-10 / Clin. Cancer Res. 2017 07;23(13):3352-3364
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-01-10 / Clin. Cancer Res. 2017 07;23(13):3352-33642017-01-10 00:00:002019-02-15 08:53:10Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients
